Patents by Inventor Mark A Hilfiker

Mark A Hilfiker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE
    Publication number: 20200095217
    Abstract: Disclosed are compounds having the formula: wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.
    Type: Application
    Filed: October 17, 2019
    Publication date: March 26, 2020
    Inventors: Sarah E. DOWDELL, Hilary Schenck EIDAM, Mark ELBAN, Ryan Michael FOX, Marlys HAMMOND, Mark A. HILFIKER, Tram H. HOANG, Lara KALLANDER, Brian Griffin LAWHORN, Sharada MANNS, Joanne PHILP, David G. WASHBURN, Guosen YE
  • Hydroxy formamide derivatives and their use
    Patent number: 10450288
    Abstract: Disclosed are compounds having the formula: wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: October 22, 2019
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Sarah E. Dowdell, Hilary Schenck Eidam, Mark Elban, Ryan Michael Fox, Marlys Hammond, Mark A. Hilfiker, Tram H. Hoang, Lara Kallander, Brian Griffin Lawhorn, Sharada Manns, Joanne Philp, David G. Washburn, Guosen Ye
  • N-HYDROXYFORMAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THEM FOR USE AS BMP l, TLL1 AND/OR TLL2 INHIBITORS
    Publication number: 20180362485
    Abstract: Compounds of Formulas (I) and (II): and salts thereof; methods of making and using the same, including use for inhibiting BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.
    Type: Application
    Filed: July 8, 2016
    Publication date: December 20, 2018
    Inventors: Carla A. DONATELLI, Sarah E. DOWDELL, Mark ELBAN, Mark A. HILFIKER, Tram H. HOANG, Dennis Alan HOLT, Sharada MANNS, Andrew MARCUS, Craig POTTEIGER, Raynold SHENJE, David G. WASHBURN
  • HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE
    Publication number: 20160340328
    Abstract: Disclosed are compounds having the formula: wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.
    Type: Application
    Filed: January 9, 2015
    Publication date: November 24, 2016
    Inventors: Sarah E. DOWDELL, Hilary Schenck EIDAM, Mark ELBAN, Ryan Michael FOX, Marlys HAMMOND, Mark A. HILFIKER, Tram H. HOANG, Lara KALLANDER, Brian Griffin LAWHORN, Sharada MANNS, Joanne PHILP, David G. WASHBURN, Guosen YE
  • TRPV4 antagonists
    Patent number: 9487507
    Abstract: The present invention relates to spirocarbamate analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: November 8, 2016
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Carl Brooks, Mui Cheung, Hilary Schenck Eidam, Krista B. Goodman, Marlys Hammond, Mark A. Hilfiker, Jaclyn R. Patterson, Patrick Stoy, Guosen Ye
  • TRPV4 antagonists
    Patent number: 9187464
    Abstract: The present invention relates to spirocarbamate compounds of Formula (I) in which R1, (R2)Y, R3, R4, X and A have the meanings given in the specification. The invention further provides pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and relates to their use of these compounds as TRPV4 antagonists in treating or preventing conditions associated with TRPV4 imbalance.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: November 17, 2015
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Carl Brooks, Mui Cheung, Hilary Schenck Eidam, Krista B. Goodman, Marlys Hammond, Mark A. Hilfiker, Tram H. Hoang, Jaclyn R. Patterson, Patrick Stoy, Guosen Ye
  • TRPV4 ANTAGONISTS
    Publication number: 20140121206
    Abstract: The present invention relates to spirocarbamate compounds of Formula (I) in which R1, (R2)Y, R3, R4, X and A have the meanings given in the specification. The invention further provides pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and relates to their use of these compounds as TRPV4 antagonists in treating or preventing conditions associated with TRPV4 imbalance.
    Type: Application
    Filed: June 15, 2012
    Publication date: May 1, 2014
    Applicant: GlaxoSmithKliine, LLC
    Inventors: Carl Brooks, Mui Cheung, Hilary Schenck Eidam, Krista B. Goodman, Marlys Hammond, Mark A. Hilfiker, Tram H. Hoang, Jaclyn R. Patterson, Patrick Stoy, Guosen Ye
  • TRPV4 ANTAGONISTS
    Publication number: 20140113916
    Abstract: The present invention relates to spirocarbamate analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Application
    Filed: June 15, 2012
    Publication date: April 24, 2014
    Applicant: GlaxoSmithKLine, LLC
    Inventors: Carl Brooks, Mui Cheung, Hilary Schenck Eidam, Krista B. Goodman, Marlys Hammond, Mark A. Hilfiker, Jaclyn R. Patterson, Patrick Stoy, Guosen Ye
  • TRPV4 antagonists
    Patent number: 8658636
    Abstract: The present invention relates to quinoline analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: February 25, 2014
    Assignee: GlaxoSmithKline, LLC
    Inventors: Carl A. Brooks, Mui Cheung, Hilary S. Eidam, Ryan M. Fox, Mark A. Hilfiker, Eric S. Manas, Guosen Ye
  • TRPV4 ANTAGONISTS
    Publication number: 20130012499
    Abstract: The present invention relates to quinoline analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Application
    Filed: March 23, 2011
    Publication date: January 10, 2013
    Applicant: GlaxoSmithKline LLC
    Inventors: Carl A. Brooks, Mui Cheung, S. Eidam Hilary, Ryan M. Fox, Mark A. Hilfiker, Eric S. Manas
  • Preparation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors
    Patent number: 7547779
    Abstract: Novel inhibitors of Rho-kinases are disclosed.
    Type: Grant
    Filed: October 6, 2004
    Date of Patent: June 16, 2009
    Assignee: Glaxo Group Limited
    Inventors: Dennis Lee, Robert A. Stavenger, Krista B. Goodman, Mark A. Hilfiker, Haifeng Cui, Andrew Q. Viet, Joseph P. Marino
  • Preparation of 1,6-Disubstituted Azabenzimidazoles as Kinase Inhibitors
    Publication number: 20080234261
    Abstract: Novel inhibitors of Rho-kinases are disclosed.
    Type: Application
    Filed: October 6, 2004
    Publication date: September 25, 2008
    Inventors: Dennis Lee, Robert A. Stavenger, Krista A. Goodman, Mark A. Hilfiker, Haifeng Cui, Andrew Q. Viet, Joseph P. Marino
  • Imidazopyridine derivatives as kinase inhibitors
    Patent number: 7348339
    Abstract: A compound of the formula and physiologically acceptable salts and or N-oxides thereof wherein, X1 is N or CR3; X2 is N or CR4; X3 is N or CR5; X4 is N or CR6. with the proviso that at least one but not more than two of X1, X2, X3 and X4 represents N. R1 is a 5-, or 6-membered heterocyclic group selected from group a, b, c or d wherein X5 is a group selected from N or CR7 and X6 is a group selected from O, S or NR8; X7 and X8 which may be the same or different is a group selected from N or CR9; X9 is a group selected from O, S or NR8 and X10 is N or CR10; X11, X12 and X13 may be the same or different and selected from a group N or CR11; processes for their preparation, pharmaceutical compositions containing them and their use in medicine.
    Type: Grant
    Filed: March 21, 2003
    Date of Patent: March 25, 2008
    Assignee: Glaxo Group Limited
    Inventors: Nicholas Bailey, Mark James Bamford, Haifeng Cui, Stephen Garland, Krista B Goodman, Mark A Hilfiker, Dennis Lee, Terence Aaron Panchal, Robert A Stavenger, David Matthew Wilson, Jason Witherington
  • Preparation of 1,7-disubstituted azabensimidazoles as kinase inhibitors
    Publication number: 20070123561
    Abstract: Novel inhibitors of Rho-kinases are disclosed.
    Type: Application
    Filed: October 6, 2004
    Publication date: May 31, 2007
    Inventors: Dennis Lee, Robert Stavenger, Krista Goodman, Mark Hilfiker, Haifeng Cui, Joseph Marino
  • Imidazopyridine derivatives as kinase inhibitors
    Publication number: 20050197328
    Abstract: A compound of the formula and physiologically acceptable salts and or N-oxides thereof wherein, X1 is N or CR3; X2 is N or CR4; X3 is N or CR5; X4 is N or CR6. with the proviso that at least one but not more than two of X1, X2, X3 and X4 represents N. R1 is a 5-, or 6-membered heterocyclic group selected from group a, b, c or d wherein X5 is a group selected from N or CR7 and X6 is a group selected from O, S or NR8; X7 and X8 which may be the same or different is a group selected from N or CR9; X9 is a group selected from O, S or NR8 and X10 is N or CR10; X11, X12 and X13 may be the same or different and selected from a group N or CR11; processes for their preparation, pharmaceutical compositions containing them and their use in medicine.
    Type: Application
    Filed: March 21, 2003
    Publication date: September 8, 2005
    Inventors: Nicholas Bailey, Mark Bamford, Haifeng Cui, Stephen Garland, Krista Goodman, Mark Hilfiker, Dennis Lee, Terence Panchal, Robert Stavenger, David Wilson, Jason Witherington